Skip to content
Disclosery

ENAVATE SCIENCES GP, LLC

Follow

13F filer, CIK 1953107, New York, NY

ENAVATE SCIENCES GP, LLC reported $327,524,118 across 7 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001953107-25-000014

Period
2025-09-30
Reported value
$328M
Holdings
7
Top 10 weight
100%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BBOTnew+2,626,946$30.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001953107-25-000014, largest first. % of portfolio is the value over $327,524,118, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,761,359 shares; 2025Q1: 3,761,359 shares; 2025Q2: 3,761,359 shares; 2025Q3: 3,761,359 shares 3,761,359$83.5M25.49%0Timeline
SIONSIONNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 2,478,030 shares; 2025Q2: 2,478,030 shares; 2025Q3: 2,478,030 shares 2,478,030$72.9M22.25%0Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,478,261 shares; 2025Q1: 4,768,583 shares; 2025Q2: 4,768,583 shares; 2025Q3: 4,768,583 shares 4,768,583$55.8M17.05%0Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,459,703 shares; 2025Q1: 2,459,703 shares; 2025Q2: 2,459,703 shares; 2025Q3: 2,459,703 shares 2,459,703$46.3M14.13%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,626,946 shares 2,626,946$30.4M9.29%newTimeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 7,788,150 shares; 2025Q1: 7,788,150 shares; 2025Q2: 7,788,150 shares; 2025Q3: 7,788,150 shares 7,788,150$27.3M8.32%0Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,785,802 shares; 2025Q1: 3,785,802 shares; 2025Q2: 3,785,802 shares; 2025Q3: 3,785,802 shares 3,785,802$11.4M3.47%0Timeline

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001953107-25-000014 base2025-11-14acceptance time not in the bulk data set